ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

PSGL-1-mTOR-TIM3 Signaling in a Murine Model of Hindlimb Transplantation

K. Kadono1, F. Messner2, J. He2, Y. Guo2, B. Oh2, G. Brandacher2, J. Kupiec-Weglinski1

1UCLA Medical Center, Los Angeles, CA, 2Johns Hopkins UJohns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2022 American Transplant Congress

Abstract number: 960

Keywords: Graft survival, Immunosuppression, T cell activation

Topic: Basic & Clinical Science » Basic & Clinical Science » 20 - VCA

Session Information

Session Name: VCA

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Peri-transplant tissue damage driven by innate-adaptive immune cascades resulting from ischemia-reperfusion injury (IRI) is a major concern in vascularized composite allotransplantation (VCA). Here, we targeted the endothelial CD62 – T-cell CD162 signaling pathway with a recombinant soluble form of a tandem-PSGL-1 (TSGL-Ig) to monitor organ preservation-triggered early/late immune responses in VCAs.

*Methods: Orthotopic hindlimb transplantation studies were performed to determine the significance of CD62-CD162 signaling in the context of innate/adaptive immune activation in syngeneic (BL6->BL6) vs. allogeneic (Balb/c->BL6) mouse models with/without TSGL-Ig during 24h cold-storage (UW). To determine whether TSGL-Ig promotes CD4+ T cell exhaustion, allo-VCAs pre-conditioned with TSGL-Ig, were treated with adjunctive anti-TIM3 Ab. Some TSGL-Ig treated allo-VCAs were conditioned with Rapamycin (Rapa), an mTOR inhibitor, to determine whether targeting endothelial CD62 – T-cell CD162 by TSGL-Ig synergizes with immunosuppressive Rapa. Skin and muscle samples were collected and analyzed at 24h post-transplant.

*Results: Treatment with TSGL-Ig exerted anti-inflammatory function in the skin and inhibited thrombosis in the muscle of syn-VCAs. By contrast, TSGL-Ig treated allo-VCAs showed a more remarkable improvement, evidenced by decreased H&E scores (p<0.05), and suppressed T-cell activation markers (e.g. IFNg, T-Bet and CD4/8), as detected by qPCR. TSGL-Ig treatment also led to higher TIM-3 gene expression while mTOR signaling was down-regulated. Anti-TIM3 Ab used as an adjunctive therapy increased tissue damage and T-cell activation, as compared with TSGL-Ig monotherapy, suggesting the beneficial effect of TSGL-Ig may relate to TIM-3 - mTOR axis. Interestingly and by contrast, TSGL-Ig failed to attenuate VCA-induced tissue damage with unchanged TIM-3 levels in allo-VCA groups conditioned with Rapa, suggesting TSGL-Ig improved VCA was mTOR-TIM-3 signaling dependent. Skin samples from Rapa + TSGL-Ig regimen showed increased T-cell activation and inferior long-term VCA survival. Lastly, TSGL-Ig failed to up-regulate TIM-3 in syn-VCA, suggesting TIM-3 signaling is essential in an adaptive immune response in allo-VCA.

*Conclusions: Our results identify the PSGL-1-TIM-3 signaling axis as a novel regulator of adaptive immunity in VCA, with mTOR being the critical checkpoint of this pathway.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Kadono K, Messner F, He J, Guo Y, Oh B, Brandacher G, Kupiec-Weglinski J. PSGL-1-mTOR-TIM3 Signaling in a Murine Model of Hindlimb Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/psgl-1-mtor-tim3-signaling-in-a-murine-model-of-hindlimb-transplantation/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences